Expression of DNMTs in non-cancerous brain tissue specimen and in malignant glioma.

<p>cDNA was synthesized from amplified RNA purified from tumor tissue obtained by stereotactic biopsy or open surgery and expression of DNMTs was determined using real-time PCR. <b>A:</b> Expression pattern of DNMTs in normal brain tissue (1, N = 10) and in high grade glioma (2, N = 63). DNMT mRNA expression is calculated relative to the reference genes <i>SDHA</i> and <i>TBP</i> (*, p>0.01). <b>B:</b> Expression of DNMTs in non-cancerous brain tissue specimen (1, N = 10), in high grade glioma (2, N = 63), and in the glioma group stratified by <i>MGMT</i> promoter methylation status (methylated, 3, N = 32; unmethylated, 4, N = 31). All data were normalized to the reference genes SDHA and TBP, and the fold change of every DNMT relative to the median expression in the normal brain samples (arbitrarily set to 1) was calculated. Horizontal bars indicate medians.</p

Study population.

<p>Abbreviations: KPS, Karnofsky performance score; PE, stereotactic biopsy; OP, open tumor resection.</p><p>*after 3 months.</p

MGMT mRNA expression and MGMT promoter methylation status in malignant glioma.

<p>Horizontal bars indicate medians. The dotted line indicates the cut-off value distinguishing low from high MGMT expression values. <b>A:</b> Expression of MGMT determined with quantitative real-time PCR in non-cancerous brain tissue specimen (1, N = 10), in malignant glioma (2, N = 63), and in the glioma group stratified by <i>MGMT</i> promoter methylation status (methylated, 3, N = 32, and unmethylated, 4, N = 31). cDNA was synthesized from amplified RNA purified from tumor tissue obtained by stereotactic biopsy or open surgery and relative expression of MGMT with respect to expression of the reference genes <i>SDHA</i> and <i>TBP</i> was determined using real-time PCR. <b>B:</b> Validation set obtained from the TCGA database. All data were derived from array analyses and expression levels of methylated (3, N = 105) and unmethylated (4, N = 104) GBM tissue samples are shown.</p

Favorable prognostic factors (uni- and multivariate models).

<p>Favorable prognostic factors (uni- and multivariate models).</p

Kaplan-Meier estimates of 63 patients with malignant glioma.

<p>Tumor tissue obtained either by stereotactic biopsy or by open surgery. <b>A:</b> Progression free survival and overall survival of the whole study population, <b>B:</b> Overall survival stratified by the <i>MGMT</i> promoter methylation status.</p

Kaplan-Meier estimates of patients with malignant glioma stratified by MGMT mRNA expression.

<p>Tumor tissue obtained either by stereotactic biopsy or by open surgery <b>A:</b> Progression free survival (N = 63), <b>B:</b> Overall survival (N = 63), <b>C:</b> Progression free survival of patients with methylated GBMs (N = 24) <b>D:</b> Survival of patients with methylated GBMs (N = 24).</p